Six years ago, Gilead Sciences was a company with a problem it couldn’t quite name. Its hepatitis C drugs had cured so many patients so quickly that the market for them was shrinking. HIV was reliable but mature. The stock drifted. Then, in a single calendar year, the company spent roughly $26 billion on two acquisitions, caught a pandemic tailwind from a COVID antiviral, and bet its next decade on cancer drugs it hadn’t yet proven. That was 2020. The question hanging over every Gilead filing since then is whether those bets are paying off, or whether the company simply bought its way into complexity.
The answer, as of the 10-Q filed for the quarter ended June 30, 2026, is: mostly yes, with one enormous asterisk on the income statement.
What the numbers say
The underlying business is growing at a healthy clip, with HIV accelerating and oncology beginning to deliver. The stock’s price-to-sales ratio sits at the 97th percentile of its own decade, meaning the market is paying a historically high price relative to revenue. Yet the trailing price-to-earnings ratio is deeply negative, because a single line item, roughly $11 billion in acquisition-related charges, swamped the income statement. Those two readings cannot both be right for long, and the gap between them is the story.
The $26 Billion Wager, Placed in a Single Year
In March 2020, Gilead paid about $4.9 billion for Forty Seven, a small immuno-oncology company whose lead asset was a cancer therapy still in early trials. Eight months later, it closed a roughly $21 billion purchase of Immunomedics, whose prize was Trodelvy, an antibody-drug conjugate, meaning a molecule that delivers chemotherapy directly to cancer cells while sparing healthy tissue. That’s the kind of targeted approach that has reshaped oncology over the past decade. Gilead was buying its seat at that table.
The timing looked audacious. The company simultaneously collected a surprise revenue surge from Veklury, its COVID antiviral, which the FDA approved for hospitalized patients in October 2020. That windfall helped fund the deals. But Veklury was always borrowed time: by mid-2026, with COVID hospitalizations low, Veklury sales had collapsed to a rounding error, down more than four-fifths year-over-year. The company had to grow into its acquisitions without that crutch. The 2026 filings show whether it has.
What the Core Business Actually Looks Like Now
Strip out the accounting charges and the picture is cleaner than the headline numbers suggest. HIV, which has always been Gilead’s engine, is running faster than it has in years. Biktarvy, the company’s flagship single-pill HIV treatment, brought in $3.8 billion in the most recent quarter alone. More striking is Descovy, an HIV prevention drug: its sales jumped nearly half in a single quarter, pushing the prevention business past a billion dollars in quarterly revenue for the first time. That’s a franchise that was already large, now accelerating.
The oncology bet is also showing returns. Trodelvy sales grew by more than a quarter year-over-year in the most recent quarter, and the drug’s label keeps expanding. The FDA and the European Commission both approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer in June 2026, according to The Motley Fool’s September 5, 2026 report. A broader label means more patients eligible for the drug, which means a larger addressable market. The Immunomedics acquisition is no longer a promise; it’s a revenue line.
The liver disease portfolio, once dominated by hepatitis C drugs that were curing their own customers out of existence, has found new life. Livdelzi, a treatment for a chronic liver disease called primary biliary cholangitis, more than doubled its sales in the most recent quarter. And in May 2026, the FDA granted accelerated approval to Hepcludex for chronic hepatitis delta, adding another product to a franchise that needed fresh entries. The old hepatitis C business is still shrinking, but the replacement parts are arriving.
Not everything is working. Cell therapy sales fell meaningfully year-over-year, reflecting competitive pressure in a crowded market. That’s a segment to watch, not yet a crisis, but a sign that Gilead’s oncology diversification is uneven.
The Asterisk: $11 Billion That Isn’t What It Looks Like
Here is where the income statement gets confusing, and where the distinction between “the math” (what filed fundamentals justify) and “the mood” (what the market is currently paying) becomes essential to hold in mind.
Gilead reported a GAAP operating loss of more than ten billion dollars in the most recent quarter. That number looks catastrophic. It is also, in a meaningful sense, an accounting artifact. The charge comes from acquired in-process research and development, a rule that requires companies to immediately expense the value assigned to pipeline drugs acquired through deals, even if those drugs may generate revenue for decades. Think of it like buying a house and being required to write off the entire purchase price on day one, even though the house still exists and you still own it. The cash didn’t vanish; the accounting says it did.
The cash flow statement tells a different story. Operations generated $3.6 billion in the three months ended June 30, 2026. That’s real money moving through the business, and it’s the number that reflects whether Gilead’s products are actually earning their keep. They are.
The tension is in the balance sheet. Cash and liquid securities fell sharply from the end of 2025 to mid-2026 as the company funded acquisitions, leaving a fraction of what it held before. Long-term debt stands at $23.8 billion, as reported in the 10-Q for the quarter ended June 30, 2026, a substantial load relative to the company’s cash position of $3.2 billion, which means Gilead is carrying a significant load. The quarterly dividend continues, and the company repurchased a meaningful slug of stock in the quarter, signals of confidence in cash generation, but also obligations that leave less room for error.
The Pipeline Bet That’s Still Being Placed
In late August 2026, the FDA approved Bixlenvo, a new once-daily single-tablet HIV regimen combining two of Gilead’s compounds, following positive Phase 3 trial results. That’s Gilead’s third FDA approval in a short stretch, and it extends the company’s grip on the HIV market just as competitors are circling. The more speculative catalyst is anito-cel, a cell therapy for multiple myeloma, with a PDUFA date, meaning an FDA decision deadline, of December 23, 2026. If approved, it would give the struggling cell therapy segment a new anchor.
Gilead and Merck also announced positive Phase 3 results in June 2026 for a once-weekly oral HIV regimen combining islatravir and lenacapavir, per the Q2 2026 earnings call transcript on Seeking Alpha. A weekly pill for HIV would be a meaningful convenience improvement over daily dosing, and Gilead’s HIV franchise has historically converted clinical wins into durable revenue.
The Price the Market Is Paying
At roughly $144 per share, the stock trades at a price-to-sales ratio of 6.2, sitting at the 97th percentile of its own decade, according to our data. That means the market is paying more per dollar of Gilead’s revenue than it has in almost any year of the past ten. The price-to-earnings ratio is effectively meaningless right now because of the acquisition charges, but the underlying earnings multiple is roughly in line with the decade median, suggesting the market is not pricing in a collapse, but is paying a premium on the sales side that the business hasn’t yet fully earned.
The Motley Fool, writing in August 2026, called Gilead an “underrated turnaround story,” citing dividend growth and cash conversion. Simply Wall St, in September 2026, suggested the stock still appears undervalued. Third-party observers have noted varying views: as of September 11, 2026, the median analyst estimate compiled by Ticker Nerd was $160, with a majority of tracked analysts carrying buy-equivalent ratings, a consensus that, per those analysts, rests on HIV acceleration and pipeline catalysts holding. BullScope does not adopt or endorse those ratings; they are reported here as context for how the market is currently positioned.
If full-year 2026 product sales land near the midpoint of management’s guided range, as stated on the Q2 2026 earnings call, and if the decade-median price-to-sales multiple were to reassert itself, the implied price would be materially lower than today’s. The mood is paying a premium the math hasn’t yet earned at the sales level. Whether the earnings trajectory, once the acquisition charges roll off, closes that gap is the open question the filed numbers raise but cannot yet resolve.
Reading the Numbers
- Q2 2026 product sales: $7.6 billion, up 8% year-over-year. This is what Gilead’s drugs actually brought in from customers in a single quarter. Eight percent growth means the business is expanding faster than the broader economy, driven almost entirely by HIV and oncology. A company growing at this rate is not stagnant; the question is whether the stock price already reflects that.
- GAAP operating loss of $10.4 billion in Q2 2026. This is the headline number that looks alarming. It is almost entirely explained by $11.2 billion in acquisition-related charges that accounting rules require to be expensed immediately. Think of a restaurant that buys a building for $1 million and must write it off on day one: the restaurant still owns the building, still serves customers, still collects revenue. The loss is real on paper; the business underneath it is not losing money at that rate.
- Operating cash flow: $3.6 billion for the quarter. This is the number that shows how much actual cash the business generated after paying its bills. For context, that’s roughly $14 billion annualized, from a company whose entire market value is around $180 billion. A household earning $140,000 a year and generating $14,000 in free cash after expenses is running a tight but functional budget. Gilead is doing something similar, at scale.
- Price-to-sales ratio: 6.2, at the 97th percentile of the past decade (our data). The price-to-sales ratio is the price tag per dollar of annual revenue. At 6.2, the market is paying $6.20 for every $1 of Gilead’s yearly sales. The decade median is $3.60. That gap means the stock is priced for a future that is considerably better than the average of the past ten years. Whether the HIV acceleration and oncology pipeline justify that premium is the central question the filed numbers raise but cannot yet answer.
- Long-term debt: $23.8 billion; cash: $3.2 billion. Net debt, meaning what’s owed minus what’s on hand, is roughly $20.6 billion. That’s a meaningful obligation relative to the company’s cash generation. A household earning $75,000 a year carrying $75,000 in debt is manageable if income is stable and growing. Gilead’s income is growing, but the margin for error is narrower than it was before the 2026 acquisitions.
Reading the numbers
$7.6 billion in quarterly product sales, up 8% year-over-year. This is the most direct measure of whether Gilead’s drugs are actually selling. Eight percent growth in a single quarter means the business is expanding at roughly four times the pace of the broader economy. The number matters here because it sits in sharp contrast to the headline loss: a company whose products are growing this fast is not in operational trouble, even if the income statement looks dire. The growth is concentrated in HIV, which tells you the core franchise is not fading.
A GAAP operating loss of $10.4 billion, driven by $11.2 billion in acquisition charges. This is the number that makes Gilead look like it is collapsing, and it is also the number that most requires context. Accounting rules require companies to immediately write off the value assigned to pipeline drugs acquired through deals, even if those drugs will generate revenue for years. The charge is real in an accounting sense but does not reflect cash leaving the building. It moves the story because it makes the price-to-earnings ratio meaningless and forces anyone reading the filing to decide whether to trust the income statement or the cash flow statement. For readers assessing operational health through the lens of cash generation rather than GAAP earnings, the cash flow statement provides the more direct signal in this reporting period.
Operating cash flow of $3.6 billion for the quarter, against long-term debt of $23.8 billion. Cash flow from operations is the closest thing a non-finance reader has to a paycheck: it is what the business actually collected after paying its costs. At $3.6 billion in a single quarter, Gilead is generating real money. The debt figure matters alongside it because $23.8 billion in long-term obligations means the company is carrying a load that requires that cash generation to hold. If HIV growth stalls or a pipeline drug fails, the cushion shrinks. The gap between a strong cash flow number and a heavy debt load is the tension that makes the balance sheet worth watching.
For the standing yardsticks on Gilead Sciences: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Gilead Sciences.
Sources
- Gilead 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Gilead 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Gilead Q2 2026 earnings press release
- Gilead Q2 2026 earnings call transcript (Seeking Alpha)
- Motley Fool: Gilead’s third FDA approval (September 5, 2026)
- Analyst consensus and estimates (Ticker Nerd, September 11, 2026)
- Gilead-Immunomedics acquisition overview (MergerSight)
- Gilead-Forty Seven acquisition (Blood Cancer United)
- Analyst consensus rating (MarketBeat, September 1, 2026)
